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Abstract
Visceral leishmaniasis (VL) is the most severe form of leishmaniasis. It is endemic in 
tropical and subtropical countries and responsible for about 50,000 deaths annually. 
It is characterized by irregular fever, progressive pallor, spleen and liver growth, and 
consequent increase in abdominal volume, lymphadenopathy, anorexia, and weight 
loss. Some changes in epidermal structures can be observed such as dry, brittle and 
depigmented hair, while the eyelashes are long and silky, pale skin, and as the disease 
progresses may arise petechiae, ecchymosis, hemorrhagic suffusion, and sometimes 
jaundice. Edema appears very often, mainly in lower limbs. Hematologic changes are 
manifested by the reduction of all blood cells. Hypoalbuminemia is a frequent finding, 
while globulin increases. The patient suspected of having the disease is the one who has 
fever and splenomegaly. It is valuable  to the diagnosis of epidemiological data, history of 
irregular fever, hepatomegaly, splenomegaly, and blood disorders such as pancytopenia 
and hypoalbuminemia. In the course of the disease, bacterial infections are established, 
especially in the respiratory tract, sometimes responsible for the death. VL is a consump-
tive disease that requires specific treatment as early as possible.
Keywords: American visceral leishmaniasis, clinical manifestations
1. Introduction
American visceral leishmaniasis (AVL) is a systemic protozoan infection characterized by 
fever, malaise, adynamia, and weight loss, besides splenomegaly, hepatomegaly, anemia, 
leukopenia, pancytopenia, and hypergammaglobulinemia. Later, cachexia, hepatic dysfunc-
tion with jaundice, hypoalbuminemia, and edema also arises. If untreated, almost always 
progresses to death [1].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Visceral leishmaniasis (VL) is the most severe form of leishmaniasis, endemic in tropical and sub-
tropical countries. It is estimated that there are 200,000–400,000 cases of VL each year worldwide, 
90% of these cases are from Bangladesh, Brazil, Ethiopia, India, Sudan, and South Sudan [2].
American visceral leishmaniasis is similar to that found in the Mediterranean region regard-
ing the etiologic agent, the animals reservoir, domestic and wild canidae, and the concen-
tration of cases in people under 10 years old [3]. The signs and symptoms are also similar 
whatever the region the disease is found. Some differences are observed such as blackened 
skin (India and Sudan) and bulky lymph nodes, mainly in Sudan, whose aspiration is used for 
diagnosis, while the skin of patients in Americas reminds aged wax and the lymph nodes are 
little bulky. In the Indian subcontinent, there is no animal reservoir; the disease is transmitted 
from one individual to another (anthroponosis) through sand flies [3].
In Latin America, VL has been found in at least 12 countries, 90% of the cases are from Brazil 
[4]. The first case described in Americas dates back to 1913 in a patient from Mato Grosso, 
diagnosed in Asuncion, Paraguay [5]. In Brazil, the first case of visceral leishmaniasis was a 
male patient, coming from Aracaju [6].
Nowadays, the disease is described from Mexico to northern Argentina. In Brazil, according to 
the Ministry of Health, 21 of the 27 Brazilian states have reported autochthonous cases. Until 
the decade of 90, 92.9% of the cases coming from Brazil were concentrated in the Northeast 
region, expanding to the North, Midwest, and Southeast regions. In 2011, only 47.8% were 
from the Northeast region [7]. In the State of Alagoas, located in the central-eastern area of 
the Northeast region, the disease occurs predominantly in the countryside, affecting mostly 
children. In recent years, VL has occurred in urban areas of several cities in Brazil.
The disease worried health authorities from the 1990s because of the increased incidence, 
urbanization, and expansion, a phenomenon observed worldwide. It is believed that some 
factors favor the expansion such as migration from rural to urban and urban to rural areas, as 
a result of agro-industrial projects, conflicts between people, and natural phenomena.
The disease can present an acute, subacute, or chronic evolution [8]. Acute leishmaniasis 
appears most often in children under 2 years old. It is manifested by a severe and continuous 
high fever and moderate spleen growth, leading to death in 3–4 months [9]. Subacute leish-
maniasis last between 6–18 months; patients have persistent fever, progressive splenomegaly, 
anemia, cachexia, and sometimes diarrhea and bronchitis. The course of VL may be modified 
by the appearance of opportunistic infections. In other patients, the course is chronic, lasting 
2 or more years, interspersed with periods of almost complete recovery; during these periods 
of apparent cure, splenomegaly is maintained [9].
The clinical course is usually divided into four periods. Despite the imprecision between them, 
it is thus considered for being a better way to comprehend in an extended period of observation 
[10]. They are incubation period, period of start or invasion, period of state, and final period.
The incubation period is difficult to characterize, patients do not know the time of the infect-
ing bite, because often there is no obvious changes. Generally, it is accepted limits between 
3–6 months [11].
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The initial period is marked by the spread of the parasite, the manifestations appear, some-
times abruptly, sometimes insidious. The patient has fever, loss of appetite, weight loss, pal-
lor, hair loss, bleeding, and apathy [11]. Fever is often the first symptom [12]. Splenomegaly 
is observed early in the course of the disease, although sometimes it is discreet. The liver also 
starts to grow. Other manifestations may dominate such as diarrheal attacks, respiratory dis-
tress, and seizures, especially in children. The signs and symptoms are unspecific and can be 
confused with other conditions.
In the state period, signs and symptoms are the same from the initial period, but more intense. 
Fever may be continuous, irregular, relapsing with remissions of 1 or more weeks and two or 
more daily peaks [13]. The anemia presented from the onset of the disease is accentuated. The 
spleen grows at the same rate of the pregnant uterus, which means 4 cm per month [14]; its 
consistency is firm and sometimes it is painful. The hepatomegaly is common but hardly ever 
reaches the size of the spleen. The hair is dry, thinned, brittle, depigmented, dull, and falls 
easily. The skin is dry, rough, and pale, remembering aged wax. The abdomen is large. Edema 
of the lower limbs and ascites can emerge as well. Even polyadenia and reduced muscle mass 
are observed. Bleeding becomes frequent. Jaundice, delayed puberty, and amenorrhea can 
also occur.
The final period is marked by the exacerbation of changes in the state period. Death may be 
caused by changes resulting from the disease itself or associated infections [10].
The etiological agent of American visceral leishmaniasis (AVL) is the protozoan Leishmania 
infantum/chagasi. It is transmitted to humans and other animals almost always by the bite of 
the female sand fly Lutzomyia longipalpis. During blood feeding on infected warm-blooded 
animals, they suck mainly foxes and dogs and become infective from 15 to 24 h. Since then, 
every new blood meal, they inoculate promastigotes, which are engulfed by macrophages 
of the monocytic phagocytic system (MPS) and become amastigotes. Inside the macro-
phages, the amastigotes are housed in phagosomes that fuse to lysosomes, giving rise to 
phagolysosomes.
Amastigotes survive and multiply in this environment, resisting to toxic substances such as 
hydrogen peroxide and hydroxyl radicals [15]. In endemic region, it is known that the inter-
action between the parasite and its host may result in individuals not infected, infected indi-
viduals free of the disease (asymptomatic carrier), and individuals who develop the disease. 
In a research work, from the total of 88 cases suspected of having the disease, 17 (19.3%) were 
infected, 24 (27.2%) were infected without the disease, and 47 (53.5%) were sick [16].
It is known that 80–90% of all human infections are asymptomatic or subclinical; these indi-
viduals have a competent cell-mediated immunity [17]. Researchers initially linked the ill-
ness to malnutrition. It is known that malnutrition weakens the defense mechanism, which 
predisposes to infectious diseases [18]. In an animal model infected with L. infantum/chagasi, 
it was found that low protein levels are associated with disease progression and lead to the 
severe form. It was also observed depletion of leucocytes, monocytes and granulocytes and 
CD4+ subpopulation. The inability to perform an efficient hematopoiesis influences the host's 
ability to combat infection [18].
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Later, it was observed that there would be other elements involved apart from malnutrition. 
It is believed that genetic factors act in determinants of susceptibility to illness and how the 
disease develops. Research shows an interrelationship between environmental and host fea-
tures [17].
This interaction between the parasite and its host can lead to equilibrium, and the host 
becomes asymptomatic carrier. It is believed that the clinical expression of disease is linked 
to susceptibility of the host, genetics of the parasite, and vector-dependent factors [18]. Some 
individuals are unable to control the spread and multiplication of parasites, developing clini-
cal manifestations of varying severity [18].
Dr. Celia Pedrosa, the author of this chapter and professor of the Medicine Faculty of Federal 
University of Alagoas, followed up patients from admission to outcome at the Tropical 
Diseases Hospital in Maceio, Alagoas/Brazil, a reference Hospital, from 1981 to 1995 [15]. By 
then, the hospital had the capacity of 80 beds, including general and intensive care, covering a 
population of 2.514.100. AVL cases were confirmed by clinical history and the identification of 
the parasite in medullary aspirate. In the cases that parasite was not found, the diagnosis was 
based on clinical manifestation and favorable response to treatment. The study included 646 
patients, 394 (61.0%) were male and 252 (39.0%) were female. The patients' ages ranged from 6 
months to 59 years, with a mean of 8.7 ± 9.4 years and a median of 5.0 years of age. Among male 
patients, the mean age was 9.8 ± 10.4 years and the median of 6.0 years (minimum 6 months 
and maximum of 59 years), and among female patients, the average age was 6.8 ± 7.0 years 
with a median of 4.0 years (minimum of 10 months and a maximum of 37 years). Table 1 shows 
the distribution of patients by age and sex.
In both genders, the highest percentage of patients consisted of children, peaking between the 
ages of 1 and 4 years and thereafter decreasing with age.
Age (years) Male Female Total
<1 15 10 25
1–5 140 128 268
5–10 103 54 157
10–15 49 31 80
15–20 21 10 31
20–30 38 12 50
30–40 18 7 25
≥40 10 0 10
Total 394 252 646
Table 1. Patients admitted to the Hospital for Tropical Diseases (Maceió-AL) with American visceral leishmaniasis, 
distributed by sex and age.
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A higher frequency of patients in the younger age groups was observed, especially before the 
age of five. Similar findings were reported by other researchers [16] who found that 60.9% of 
the viscerotomies in patients with leishmaniasis were in children under 5 years old. Other 
researchers [17, 18] found resembling data in Ceará (67%) and Bahia (75%).
The neotropical kala-azar, also known as AVL, is located in an intermediate position between 
the “Indian,” in which 62% of the cases are in people between 5 and 19 years, and the 
“Mediterranean” types, in which children under 5 account for 93% of the cases [19]. However, 
since the emergence of the human immunodeficiency virus (HIV), the use of immunosup-
pressant in transplanted patients, and chemotherapy, half of European cases are in adults [1].
Male patients have a higher incidence of the disease than female ones, whatever the age. Some 
researchers attribute this to larger male body area usually discovered [17], and consequently 
more exposed to the bite of the vectors; however, it is unlikely that only this fact explains the 
difference. Studies suggest that genetic modulation is linked to sex in the susceptibility to 
visceral leishmaniasis [20].
The most common clinical manifestation was fever. In the course of the disease, the fever is 
very variable. In general, the fever is highest early in the disease, with two or more peaks in 
24 h. As the disease is established, temperature becomes lower. Some patients, even present-
ing fever, claim not to feel it.
Among the patients admitted, the duration of the disease was obtained in 622 patients 
(Table 2). It was observed that 405 (65.1%) of them arrived at the hospital referring 30–179 
days of illness. This time is too long for a disease with marked clinical changes such as fever, 
weight loss, pallor, and increased abdominal volume. Other authors found similar data [21].
Since the onset of the disease, patients always seek medical care. However, even in endemic 
region, diagnosis is not considered and patients generally receive antimicrobials. By the irreg-
ularity of fever itself, patients may spend days or weeks with normal temperature, causing 
the false impression of cure of another infectious process, believed to be one of the reasons for 
the difficulty to know the right onset of the symptoms.
Duration of the disease Patients
(days) Number %
<30 107 17.2
30–90 238 38.3
90–180 167 26.8
180–360 73 11.8
≥360 37 5.9
Total 622 100.0
Table 2. Duration of the disease in 622 patients with American visceral leishmaniasis admitted to the Tropical Diseases 
Hospital, in Maceió-AL.
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The clinical manifestations most often found in the admission include hepatomegaly, sple-
nomegaly, fever, and pallor. Hepatomegaly’s predominance over splenomegaly draws atten-
tion, and this fact stems from a patient who inadvertently has been splenectomized. The sum 
of the clinical manifestations exceeds 100% because most of the patients had simultaneously 
more than one clinical manifestation (Table 3).
Irregular fever, generally high, and pallor were relevant, associated with increased abdominal 
volume, led patients to seek medical attention. On admission, the contrast between the hair 
and the eyelashes drew attention, because while the hair was depigmented, dry and dull 
lashes were long and silky. A Brazilian researcher studied clinical and laboratory features 
of kala-azar and also found patients with dry, brittle, depigmented hair, and long eyelashes 
[22]. According to this author, lower hyperthermia is common when the disease has a long 
duration, observation confirmed by us. However, other manifestations such as jaundice and 
edema, also observed in our study, did not maintain relation with the duration of illness.
Some researchers have noted that patients with jaundice had worse prognosis [21]. To other 
authors, not only jaundice, but also the low age, marked pallor, creatinine elevation, and pres-
ence of amastigotes in bone marrow aspirate are factors associated with poor outcome [23]. 
Clinical manifestations Number of patients %
Hepatomegaly 633 98.0
Splenomegaly 632 97.8
Fever 628 97.7
Pallor 533 82.5
Increased lymph nodes 500 77.5
Increased abdominal volume 463 71.7
Weight loss 462 71.5
Long eyelashes 454 70.3
Dry hair 450 69.7
Asthenia 447 69.2
Anorexia 416 64.4
lower limbs edema 151 23.3
Cough 104 16.2
Diarrhea 102 14.4
Abdominal pain 80 12.4
Bleeding 67 10.4
Jaundice 90 13.9
Table 3. Clinical manifestations most often observed in patients with American visceral leishmaniasis admitted to the 
Hospital for Tropical Diseases in Maceió-AL.
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However, in our study, we found no association between low age, presence of parasites in the 
bone marrow, and poor prognosis.
The spleen has firm consistency, not painful on palpation, except in some cases. Since it is a 
good parameter for estimating the duration of the disease and response to treatment, it must be 
carefully examined and its features registered on medical records. Always measure the spleen 
and liver size with a tape, describe the location of measurement, or use the Hackett scale.
Liver has firm consistency too, sometimes painful on palpation. Its size as well as the spleen 
accompanied the duration of the disease; liver is always a little lower than spleen (Table 4), 
but after the institution of specific therapy, liver regression occurred more slowly.
During the follow-up, the duration of the disease compared to spleen size measured at hospi-
tal admission (Table 5) was observed. The average size of the spleen does not correspond to 
what is expected of its size for this duration of illness. Since fever becomes continuous later, 
patients believe this illness is recent. Investigating important data, such as fever and relating 
them with celebrating days, you get more accurate information about disease’s duration.
Duration of the 
disease (days)
Number of patients Size of the liver (cm)
Mean ± standard 
deviation
Minimum Maximum
<30 105 4.2 ± 1.8 0.0 9.0
30–90 221 4.7 ± 2.2 0.0 12.0
90–180 163 5.6 ± 2.5 0.0 14.0
180–360 68 5.8 ± 3.3 0.0 16.0
≥360 36 7.3 ± 3.6 2.0 20.0
Table 4. Size of the liver in hospital admission for the duration of the disease in 593 patients.
Duration of the 
disease (days)
Number of patients Size of the spleen (cm)
Mean ± standard 
deviation
Minimum Maximum
<30 102 7.2 ± 3.3 0.0 16.0
30–90 220 8.6 ± 4.0 0.0 33.0
90–180 159 9.8 ± 3.6 0.0 20.0
180–360 66 10.3 ± 4.2 0.0 20.0
≥360 36 12.4 ± 3.8 3.0 20.0
Table 5. Size of the spleen in hospital admission for the duration of the disease in 583 patients.
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The normal spleen is rarely palpated, located on the left upper quadrant of the gastric fun-
dus and the diaphragm. In VL, spleen growth takes place since the beginning of the disease. 
Ancient authors compare its growth to the gravid uterus [24]. Based on this knowledge, for 
those patients who do not remember since when they were sick, it is possible to estimate the 
duration of the disease by spleen size. Disease duration is an important factor because the 
prognosis is directly related to the time they are sick [25].
Liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), mea-
sured at the time of admission in 444 patients, showed values above normality (>40 units/l) in 
169 (38.1%) and 258 (58, 1%) patients, respectively (Table 6). Liver enzymes that were abnor-
mal at the time of admission hold no relation to the duration of the disease. Otherwise, for 
other researchers, the aminotransferase was more pronounced in cases diagnosed late [26].
After treatment, liver enzymes returned to normal, except in four patients who died with liver 
failure. Histopathologic findings suggested toxic hepatitis.
Associated infections were diagnosed at admission in 134 (20.7%) patients. Airway infections, 
especially pneumonia, were most often found. Children under 5 years old were the most 
affected by associated infections, 104 (60.8%) cases.
During the period they were hospitalized for treatment, 258 patients developed some type of 
infection; the most frequent was pneumonia, which affected 126 (48.8%) subjects. Regardless 
of the grievance, the higher incidence of infections acquired during hospitalization occurred 
in children under 5 years old with 229 (61.4%) occurrences.
In our observation, associated infections were not related to the duration of the disease, but 
they affected mortality.
In 554 patients, we performed blood tests at hospital admission. The count of red cells ranged 
from 1.03 to 4.55 million red cells/mm3, with an average of 2,762,000 ± 620,307 red cells/mm3, 
while in 603 patients white blood cell (WBC) counts ranged from 600 to 15,600 leukocytes/mm3 
with an average of 4174 ± 2127 leukocytes/mm3. In differential counting, the absolute number 
of lymphocytes ranged from 102 to 11,100 lymphocytes/mm3 with a mean of 2339 ± 1422 lym-
phocytes/mm3. Platelets counted in 279 patients ranged from 1000 to 732,600 platelets/mm3, 
Enzymesa,b No of patients (%) Mean ± standard  
deviation (units/l)
Maximum-minimum  
(units/l)
ALT ≤ 40 275 (62.0) 19.5 ± 11.2 2.0–40.0
ALT > 40 169 (38.0) 145.5 ± 210.1 41.0–1750.0
AST ≤ 40 186 (41.9) 23.6 ± 10.2 3.0–40.0
AST > 40 258 (58.1) 126.9 ± 174.5 41.0–1530.0
a ALT, alanine aminotransferase; AST, aspartate aminotransferase.
b Normal values ≤ 40 units/l.
Table 6. Liver enzymes measured in 444 patients at hospital admission.
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with an average of 140,020 ± 103,049 platelets/mm3. Except the leukocytes, all these averages 
are below normal values. Using analysis of variance, it was observed that except the medium 
of leukocytes and lymphocytes, which were significantly higher in patients younger than 30 
days of illness, all other results showed no significance regarding disease duration (Table 7).
Our patients had varying degrees of anemia associated with leukopenia and thrombocyto-
penia. Anemia seems to occur when the spleen becomes palpable and progresses with its 
gradual increase; this opinion is shared by others [27, 28]. Anemia is one of the most remark-
able manifestations of visceral leishmaniasis, and the pathogenesis of this anemia, caused in 
part by the destruction of red blood cells, is multifactorial (splenic phagocytosis of opsonized 
erythrocytes, hemodilution, and increased destruction of normal red blood cells by hyper-
splenism) [3]. In addition, there is a bone marrow failure to replenish red blood cells removed 
from the circulation, which can be attributed to poor nutrition and infection extension.
There are several hypotheses proposed to explain the pathogenesis of anemia in visceral leish-
maniasis. Some pointed to the increased blood volume, while others argue that autoimmune 
mechanisms are responsible for the decreased survival of red blood cells. Their destruction 
occurs intensely in the spleen. Others emphasize that the reduced erythrocyte survival and 
iron deficiency are more common in children under 3 years [29, 30].
For others, the severity of hematological changes depends on the duration of the disease and 
the spleen size, hypersplenism primarily responsible for these changes. The pancytopenia 
and thrombocytopenia reflect an extended illness, before the diagnosis is made [31].
In 450 patients in which the temperature was measured during the course of treatment, 25 
(5.6%) cases showed no fever when treatment was initiated. In 330 (73.3%) cases, the tempera-
ture normalization occurred until day 7 after initiation of therapy. In 56 (12.4%), temperature 
normalized between the 8th and 14th day, and in 39 (8.7%), from 15th to 21st day.
Duration of the 
disease (days)
Hma (×103/mm3) Htb (%) Hbc (g/dl) Platelets (×105/
mm3)
Leukocytes 
(mm3 )
Lymphocytes 
(×103/mm3)
<30 2.770 ± 697 23.6 ± 6.4 7.2 ± 2.2 1.35 ± 0.78 4.872 ± 2.186 2.7 ± 1.6
30–90 2.683 ± 633 23.0 ± 5.5 7.0 ± 1.8 1.36 ± 0.11 4.168 ± 2.183 2.2 ± 1.4
90–180 2.784 ± 599 24.0 ± 5.5 7.4 ± 1.8 1.39 ± 0.99 3.962 ± 2.001 2.2 ± 1.2
180–360 2.797 ± 635 24.0 ± 6.0 7.4 ± 2.0 1.68 ± 0.12 3.763 ± 2.190 2.0 ± 1.3
≥360 2.988 ± 453 26.1 ± 4.1 8.1 ± 1.5 1.40 ± 0.88 3.955 ± 2.141 1.9 ± 1.2
pd 0.155 0.062 0.061 0.0653 0.004* 0.004*
a Red cells.
b Hematocrit.
c Hemoglobin.
d Comparation of the means (variance analysis, g.l. = 4).
* C.I.: 95%: significant differences (p < 0.05).
Table 7. Blood test data (mean ± standard deviation) of patients at admission according to the duration of the disease.
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In 630 patients who started treatment, 109 (16.8%) received incomplete treatment (62 because 
they died and 47 because they left before the treatment was completed) and 521 (80.6%) 
received full treatment. There was a death after completion of therapy. Five patients (0.7%) 
had a new treatment cycle.
Regardless of the duration of the disease, there was a decrease in the average size of liver and 
spleen after treatment. The percentage reduction of these organs at the end of treatment was 
higher in patients with less disease duration (Table 8). The analysis of variance showed that 
the spleen reduction percentage was higher in patients with less disease duration. However, 
considering the liver, this difference was not observed.
Among the patients who progressed to death, 44 (57.9%) were male and 32 (42.1%) were 
female. Forty-six of them died during the first or second weeks of treatment. The clinical 
manifestations most often related to death were bleeding, edema (anasarca and ascites), and 
pneumonia. In the third and fourth weeks, 17 deaths were registered, with a predominance of 
pneumonia as a probable cause of death.
Table 9 shows the distribution of deaths by age, including those 13 individuals who died 
before treatment was started, while Table 10 shows the distribution of deaths by disease dura-
tion. There was no statistically significant difference in the percentage of deaths in relation to 
age (χ2 = 13.64, p = 0.058, g.1. = 6). However, since p-value is close to convention (0.05), some 
different interpretation may be important, like the high mortality rates in patients under 1 
year old (33.3%). There was no statistical significance regarding disease duration (χ2 = 0.51, 
p = 0.973 , g.1. = 4).
According to observations of Brazilian researchers, the deaths occur by the delay in starting 
the treatment or lack of response to it. Advanced case can present worsening in the first days 
of treatment, resulting from Herxheimer reaction. In these patients, death occurs mostly by 
bacterial complications or bleeding [25]. In a survey of medical records at the “Hospital das 
Clinicas,” in São Paulo (Brazil), about 13% of deaths in 162 patients with visceral leishmani-
asis was found and the main causes were pneumonia and sepsis [32].
Duration of the 
disease
Spleen Liver
Number of patients % of reductiona Number of patients % of reductiona
<30 73 70.75 60 58.73
30–90 157 60.03 1248 55.41
90–180 115 53.50 86 46.17
180–360 49 54.37 42 45.64
≥360 23 52.47 16 46.61
a 100 − (mean of the viscera in the end of the treatment × 100).
Note: mean of the viscera before treatment.
Table 8. Percentage reduction in the average size of the spleen and liver after treatment.
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We did not observe an association between disease duration and the number of deaths, as 
some claim. According to a study conducted by these authors, the death was more frequent 
in cases with longer disease duration [18–23, 25–31, 33, 34]. Our mortality data are consistent 
with a study conducted in Sudan which found 12% of deaths [35].
The World Health Organization [36] considered as a factor that worsens prognosis the 
late start of treatment, especially for younger children as well as associated infections. 
However, in our study we found no relationship between disease duration or age and mor-
tality. Our data, regarding the causes of death, are comparable to other Brazilian research-
ers who have found bacterial infections in 59% of their patients; the respiratory tract was 
the most involved with 48% of the cases. These infections had no relation to the duration 
of the disease [37].
It is likely that the progress of visceral leishmaniasis, favorable or not, depends on the agent 
and the genetic constitution of the host, and therefore of the ability of the body in defending 
itself.
Age (years) Number of deaths/Total number of patients (%)
<1 8/24 (33.3)
1–5 34/256 (13.3)
5–10 18/149 (12.1)
10–15 7/79 (8.9)
15–20 2/28 (7.1)
20–30 4/47 (8.5)
30–40 3/22 (13.6)
≥40 0/10 (0.0)
Total 76/616 (12.3)
Table 9. Distribution of deaths by age in 616 patients admitted at the Tropical Diseases Hospital “Constança de Góes 
Monteiro”.
Duration of the disease (days) Number of deaths/total number of patients (%)
<30 11/102 (10.8)
30–90 25/225 (11.1)
90–180 20/157 (12.7)
180–360 7/71 (9.9)
≥360 4/36 (11.1)
Total 67/591 (11.3)
Table 10. Distribution of deaths according to the duration of the disease.
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Continuing observation over the years allows us to conclude that the duration of the disease 
is correlated to the size of the liver and spleen, the temperature, the number of leukocytes 
and lymphocytes at hospital admission, and spleen size at the end of treatment. However, 
associated infections and complications are not influenced by disease duration, as well as the 
normalization of temperature after the start of specific therapy. Finally, we find that death 
is not associated with age, sex, positive medullary puncture, or disease duration. We also 
observed that at the end of treatment, there is no full recovery, but considerable improvement 
in all clinical and laboratory parameters.
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